

References

I-74

1. Mou W, Xue H, Tong H, et.al. Prognostic value of serum leptin in advanced lung adenocarcinoma patients with cisplatin/pemetrexed chemotherapy. *Oncology Letters*. 2014 Mar 4; 7:2073-2078.
2. Zhang YM, Li YQ, Liu ZH, et.al. Clinical Efficacy of Bevacizumab Concomitant with Pemetrexed in Patients with Advanced Non-small Cell Lung Cancer. *Asian Pacific Journal of Cancer Prevention*. 2014; 15(8); 3447-3450.
3. Shah M, Winfree KB, Peterson P, et.al. Cost effectiveness for first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting. *Lung Cancer*. 2013 Jan; 82:121-127.
4. Raman P, Surmont V. Unexpected dramatic response to pretreated invasive thymic malignancies on Pemetrexed-Case report and review of current treatment modalities. *Open Journal of Respiratory Disease*. 2012 Nov; 2:107-115.
5. Raizer JJ, Rademaker A, Evens AM, et.al. Pemetrexed in the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma. *Cancer*. 2012; 118:3743-3748.
6. Pemetrexed (Alimta®) [Produce Information]. Indianapolis, IN. Eli Lilly and Company; 2013.
7. Zhong A, Xiong X, Shi M, et al. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis. *Drug Design, Development and Therapy*. 2015 Jul 20; 9:3685-93.
8. Bambury R, Benjamin D, Chaim J, et al. The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: A large single-institution experience. *The Oncologist*. 2015; 20:508–515.
9. Peters S, Adjei A, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): European Society For Medical Oncology (ESMO) clinical practice guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 23 (Supplement 7): vii56–vii64, 2012.
10. Sun Y, Wang Y, Han S, et al. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. *OncoTargets and Therapy*. 2017;2595-2600.
11. Ellis PM, Leighl NB, Hirsh V, et al. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non—Small-Cell Lung Cancer. *Clinical Lung Cancer*. 2015;457-496.
12. Hu X, Pu K, Feng X, et al. Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Plos One*. 2016;1-18.
13. MICROMEDEX®SOLUTIONS Compendia. 2017. Pemetrexed.
14. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Pemetrexed.

15. NCCN Drugs & Biologics Compendium™. Pemetrexed. 2017. National Comprehensive Cancer Network (NCCN).